Can-Fite says journal publishes data from the COMFORT-1 psoriasis study

Can-Fite BioPharma announced that the Journal of the European Academy of Dermatology and Venereology, EADV, published an article titled “Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial “. EADV is a top ranked peer reviewed journal or impact factor 9.2 ,that publishes articles on clinical and basic science topics in dermatology. Article Link. The article’s first author, Dr. K.A Papp, is an internationally renowned key opinion leader in the psoriasis field and was the engine for some registered drugs on the market for this devastating skin disease. The EADV article presents the safety and efficacy of Piclidenoson in the randomized, placebo- and active-controlled, double-blind Phase III COMFORT-1 trial. As previously reported, the study met its primary endpoint which was the proportion of patients achieving =75% improvement in Psoriasis Area and Severity Index PASI from baseline PASI-75 at Week 16…